Current treatments for Parkinson's still only provide symptomatic relief but Bayer AG is hopeful that a couple of its cell and gene therapies being developed by its wholly owned subsidiaries BlueRock Therapeutics LP and Asklepios BioPharmaceutical, Inc. could potentially offer a paradigm shift in tackling the disease.
The most excitement to date at Bayer has centered around BlueRock's bemdaneprocel, which is administered by surgical transplantation into the putamen part of the brain and has been designed to replace the dopamine-producing neurons that are lost in Parkinson’s
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?